Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

ed at the end of 2006.

Our process development expenses for the first quarter of 2008 were $35,766 compared to $89,776 for the first quarter of 2007. In the first quarter of 2008, our process development focus continues to be on the scale up to 100-litre production runs. In the first quarter of 2007, our process development focus was on our earlier 40-litre scale up studies.

We still expect that our M&P expenses for 2008 will increase compared to 2007. We have initiated our 40-litre production runs which will continue throughout 2008. As well, we still expect to finalize our 100-litre scale up studies and continue the examination of a lyophilization process for REOLYSIN(R) in 2008. Once our 100-litre process development studies are complete, we expect to transfer our 100-litre manufacturing process to our cGMP manufacturers.

Clinical Trial Program

2008 2007

$ $

-------------------------------------------------------------------------

Direct clinical trial expenses 994,646 683,107

Other clinical trial expenses 48,145 38,510

-------------------------------------------------------------------------

Clinical trial expenses 1,042,791 721,617

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the first quarter of 2008, our direct clinical trial expenses increased to $994,646 compared to $683,107 for the first quarter of 2007. In the first quarter of 2008, we incurred direct patient costs in our six enrolling clinical trials compared to only three actively enrolling clinical trials in the first quarter of 2007.

We still expect our clinical trial expenses to increase i
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
(Date:8/29/2014)... one of the most promising technologies for future quantum ... (photons) instead of electrons. First, it is necessary to ... and control their direction. Researchers around the world have ... but now scientists at the Niels Bohr Institute have ... one at a time and in a particular direction. ...
(Date:8/29/2014)... 29, 2014 The global companion ... in 2019. It is expected to grow at ... and was valued at $1.8 billion in 2013, ... Market Research. , For more information regarding analysis ... , The research report, titled “Companion Diagnostics Market ...
(Date:8/29/2014)... According to a new market report published by ... was valued at USD 3,754.6 million in 2012 and is ... a CAGR of 5.9% from 2013 to 2019. , Nearly ... afflicted by bone and joint disorders, and this number is ... and will continue to increase the demand for orthobiologics. Other ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... NeoGenomics, Inc. (OTC Bulletin Board: NGNM) today announced ... Equity Conference at 12:30 PM EDT on ... Hotel in Hollywood, FL.  Robert Gasparini, the Company,s ... NeoGenomics, market positioning, financial performance, and strategic direction and then ...
... /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", the "Company") (Nasdaq: CHBT ), the leading ... management will present at the Bank of America Merrill Lynch Health,Corporate Day. The ... Merrill,Lynch Client Service Center in Hong Kong . , ... About China-Biotics , ...
... ... The iuvo™ Chemotaxis Assay ... technology to provide quantitative measurements of neutrophil chemotaxis ( ... remains stable over the time period of the assay. ...
Cached Biology Technology:NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 2NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 3China-Biotics to Present at Bank of America Merrill Lynch Healthcare Event on June 22 2BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 2BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 3BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 4
(Date:8/29/2014)... have made some surprising discoveries about the body,s ... virus (SIV), the team found that specialized cells ... responders to viral invasion and are the source ... interleukin-1 beta (IL-1β). , Though aimed at ... the gut epithelium that provides a barrier to ...
(Date:8/29/2014)... at the Barshop Institute for Longevity and Aging Studies, ... Health Science Center at San Antonio, have found another ... rodent, the naked mole rat. , They reported ... rats protects and alters the activity of the proteasome, ... The factor also protects proteasome function in human, mouse ...
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... are single-celled organisms and a domain unto themselves, quite ... higher organisms. Many species live under extreme conditions, and ... nor with eukaryotes. Methanogenic archaeans, for example, can produce ... underlying chemical reaction, a reduction, involves the cofactor known ...
... German . A good wine needs to ripen. But ... grapevines have to overcome all kinds of obstacles. Extremely hot or rainy ... pests that can appear on the scene. Bugs such as the vine ... as the "Grapevine fanleaf virus" (GFLV for short) can give the vines ...
... of proteins that are highly effective at killing bacteria and ... antibiotics. Researchers from the Universities of York and Leeds ... Research Council (BBSRC) to find out how a family of ... before destroying them. The team, led by Professor Colin ...
Cached Biology News:Rampant helper syndrome 2Virus-resistant grapevines 2
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Mouse monoclonal antibody raised against a partial recombinant IL31RA. NCBI Entrez Gene ID = IL31RA...
...
Biology Products: